HC Wainwright & Co. Initiates Coverage On Acelyrin with Buy Rating, Announces Price Target of $44
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Emily Bodnar initiates coverage on Acelyrin (NASDAQ:SLRN) with a Buy rating and announces a price target of $44.
September 05, 2023 | 10:18 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has initiated coverage on Acelyrin with a Buy rating and a price target of $44.
The initiation of coverage by HC Wainwright & Co. with a Buy rating and a price target of $44 indicates a positive outlook for Acelyrin. This could potentially attract investors and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100